[go: up one dir, main page]

EA202090929A1 - ANTIBODIES, ACTIVATED ANTIBODIES, SPECIFIC ANTIBODIES AND SPECIFIC ACTIVATED ANTIBODIES AND METHODS OF THEIR APPLICATION - Google Patents

ANTIBODIES, ACTIVATED ANTIBODIES, SPECIFIC ANTIBODIES AND SPECIFIC ACTIVATED ANTIBODIES AND METHODS OF THEIR APPLICATION

Info

Publication number
EA202090929A1
EA202090929A1 EA202090929A EA202090929A EA202090929A1 EA 202090929 A1 EA202090929 A1 EA 202090929A1 EA 202090929 A EA202090929 A EA 202090929A EA 202090929 A EA202090929 A EA 202090929A EA 202090929 A1 EA202090929 A1 EA 202090929A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
activated
specific
methods
application
Prior art date
Application number
EA202090929A
Other languages
Russian (ru)
Inventor
Лейла Мери Бустани
Шери Л. Ла Порт
Брайан А. Ирвинг
Джинн Грейс Фландез
Original Assignee
Цитомкс Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Цитомкс Терапьютикс, Инк. filed Critical Цитомкс Терапьютикс, Инк.
Priority claimed from PCT/US2018/055717 external-priority patent/WO2019075405A1/en
Publication of EA202090929A1 publication Critical patent/EA202090929A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

В изобретении представлены антитела, активируемые антитела (АА), биспецифические антитела и биспецифические активируемые антитела (ВАА). Также в данном документе представлены способы получения и способы применения таких антител, АА, биспецифических антител и ВАА.The invention provides antibodies, activated antibodies (AA), bispecific antibodies and bispecific activated antibodies (BAA). Also provided herein are methods of making and methods of using such antibodies, AA, bispecific antibodies, and BAA.

EA202090929A 2018-09-14 2018-10-12 ANTIBODIES, ACTIVATED ANTIBODIES, SPECIFIC ANTIBODIES AND SPECIFIC ACTIVATED ANTIBODIES AND METHODS OF THEIR APPLICATION EA202090929A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731622P 2018-09-14 2018-09-14
PCT/US2018/055717 WO2019075405A1 (en) 2017-10-14 2018-10-12 Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
EA202090929A1 true EA202090929A1 (en) 2020-07-06

Family

ID=71833520

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090929A EA202090929A1 (en) 2018-09-14 2018-10-12 ANTIBODIES, ACTIVATED ANTIBODIES, SPECIFIC ANTIBODIES AND SPECIFIC ACTIVATED ANTIBODIES AND METHODS OF THEIR APPLICATION

Country Status (1)

Country Link
EA (1) EA202090929A1 (en)

Similar Documents

Publication Publication Date Title
EA202092839A1 (en) PSMA LINKING AGENTS AND THEIR APPLICATIONS
EA202190609A1 (en) ANTIBODIES AGAINST HLA-G, COMPOSITIONS CONTAINING ANTIBODIES AGAINST HLA-G, AND METHODS OF APPLICATION ANTIBODIES AGAINST HLA-G
MX2018008934A (en) Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same.
EA202091130A1 (en) LYOPHILIZED PREPARATION OF MONOCLONAL ANTIBODY TO TRANSTYRETIN
PH12020550243A1 (en) Anti-tau antibodies and uses thereof
EA201890302A1 (en) CHEMICAL ANTIGEN RECEPTORS BASED ON SINGLE-DOMAIN ANTIBODIES AND METHODS OF THEIR APPLICATION
EA201891992A1 (en) CHIMERIC RECEPTORS AND WAYS OF THEIR APPLICATION
EA201891694A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING THE STRUCTURES OF BISPECIFIC ANTIBODIES
MX2020010951A (en) Anti-hla-g antibodies and use thereof.
EA201792467A1 (en) HETERODIMERNYE ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
EA201692539A1 (en) ANTIBODIES AND ANTIGENS-BINDING FRAGMENTS, WHICH SPECIFICALLY CONNECT WITH THE PROUCH OF TAU ASSOCIATED WITH MICROTUBULES
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
EA202191763A1 (en) BIFUNCTIONAL ANTI-PD-1/SIRP MOLECULE
EA202191785A1 (en) ANTIBODIES TO CTLA4 AND METHODS OF THEIR APPLICATION
EA201991876A1 (en) ANTIBODIES AGAINST FACTOR D AND THEIR APPLICATION
PH12019502298A1 (en) Monoclonal antibody to pd-l1
CR20200404A (en) Anti-klk5 antibodies and methods of use
EA201791691A1 (en) SINGLE-DOMAIN ANTIBODIES DIRECTED TO CD1d
MX2020011027A (en) CONSTRUCTS OF TRIVALENT BISECIFIC ANTIBODIES.
EA201892716A1 (en) Antibody to Coagulation Factor XI
EA201792220A1 (en) ANTIBODY-MEDIATED NEUTRALIZATION OF THE CHICUNG VIRUS VIRUS
CO2022004797A2 (en) Anti-klk7 antibodies, anti-klk5 antibodies, anti-klk5/klk7 multispecific antibodies and methods of use
PH12020552270A1 (en) Anti-steap1 antigen-binding protein
EA201992460A1 (en) BTLA ANTIBODY ANTIBODIES AND THEIR APPLICATION
CR20230581A (en) Anti-ccr8 antibodies and uses thereof